Apr 22, 2019· Comment from Association for Accessible Medicines· FDA-2019-D-0065-0008
The Association for Accessible Medicines is pleased to provide comments to the Food and Drug Administration on its draft guidance for industry on the competitive generic therapy (CGT) pathway established by the FDA Reauthorization Act of 2017 (FDARA). See attached file(s)